Imagine a world where a rare genetic eye disease that blinds young boys could be reversed with a single injection. That world just became reality. On June 11, 2026, West China Hospital of Sichuan University published landmark clinical trial results in The New England Journal of Medicine (NEJM), demonstrating successful subretinal gene therapy for X-linked retinoschisis (XLRS)—a devastating inherited retinal disorder that causes progressive vision loss in males starting from childhood.
What is X-Linked Retinoschisis?
A Rare but Devastating Inherited Condition
X-linked retinoschisis (XLRS) is a recessive genetic disorder caused by mutations in the RS1 gene, which encodes retinoschisin—a protein essential for maintaining the structural integrity of the retina. The condition predominantly affects males and is characterized by progressive macular degeneration, leading to significant vision loss.
The disease typically manifests in childhood, with patients experiencing splitting (schisis) of the retinal layers, particularly affecting the macula—the central part of the retina responsible for sharp, detailed vision. Without intervention, many patients progress to legal blindness by middle age.
XLRS affects approximately 1 in 5,000 to 1 in 25,000 males worldwide, making it one of the more common causes of juvenile macular degeneration in this population. Until now, treatment options were limited to managing complications and providing visual aids—there was no cure.
The Gene Therapy Breakthrough
How the Treatment Works
The groundbreaking therapy uses a subretinal injection of scAAV8-hRS1—a self-complementary adeno-associated virus (AAV) vector carrying a functional copy of the RS1 gene. This delivery method allows the corrected gene to reach the retinal cells directly, where it can begin producing the missing retinoschisin protein.
The AAV8 serotype was specifically chosen for its excellent tropism for retinal cells and its established safety profile in ocular gene therapy applications. The “sc” prefix indicates “self-complementary,” a design that enables faster and more efficient gene expression compared to traditional single-stranded AAV vectors.
Subretinal injection is a delicate surgical procedure that delivers the therapeutic vector directly into the potential space between the neurosensory retina and the retinal pigment epithelium. This precise delivery ensures maximum contact between the vector and target retinal cells while minimizing exposure to other tissues.
Clinical Trial Results
Encouraging Outcomes from 12 Patients
The NEJM publication reports results from 12 male patients who received the gene therapy treatment. The study, conducted by a team led by Dr. Liang L and colleagues from West China Hospital’s Department of Ophthalmology in collaboration with the State Key Laboratory of Biotherapy, represents the first successful clinical trial of gene therapy for XLRS published in a top-tier medical journal.
Key findings from the clinical trial include:
- Improved visual acuity in treated patients
- Reduction in retinal schisis cavities observed on optical coherence tomography (OCT)
- Restored retinoschisin protein expression in the retina
- Acceptable safety profile with no serious adverse events related to the gene therapy
The study demonstrated that subretinal gene therapy with scAAV8-hRS1 could effectively deliver functional RS1 genes to retinal cells, leading to meaningful clinical improvements in patients with this previously untreatable condition.
Significance of NEJM Publication
Publication in The New England Journal of Medicine—widely regarded as one of the most prestigious and influential medical journals globally—validates the scientific rigor and clinical significance of this research. With an impact factor of 158.5, NEJM acceptance indicates that this gene therapy approach has undergone rigorous peer review and represents a genuine advancement in ophthalmic medicine.
What This Means for Patients
Hope for Thousands of Families
For families affected by XLRS, this breakthrough offers the first real hope of treatment. Previously, parents could only watch as their sons’ vision deteriorated over time. Now, there is a potential pathway to not just slow progression, but actually improve visual function.
The success of this trial opens doors for:
- Earlier intervention: With a proven treatment option, genetic testing and early diagnosis become even more critical
- Broader applications: The techniques developed for XLRS could potentially be adapted for other inherited retinal diseases
- Global access: As the therapy moves through regulatory approval processes, patients worldwide may benefit
Next Steps for Clinical Development
While this Phase I/II trial demonstrates proof of concept, larger Phase III trials will be needed to confirm efficacy and safety in a broader patient population. Patients interested in participating in future clinical trials should consult with their ophthalmologists and consider genetic testing to confirm XLRS diagnosis.
West China Hospital’s Achievement
Leading the Way in Gene Therapy Research
West China Hospital of Sichuan University, consistently ranked among China’s top hospitals and one of the largest single-site hospitals in the world, has established itself as a leader in gene therapy research. This NEJM publication adds to the institution’s growing portfolio of high-impact clinical research.
The successful XLRS gene therapy trial represents a collaborative effort between:
- West China Hospital’s Department of Ophthalmology
- State Key Laboratory of Biotherapy
- Multiple research teams specializing in vector development and clinical trial design
This achievement demonstrates China’s growing capabilities in advanced therapeutic development and positions West China Hospital as a destination for patients seeking cutting-edge ophthalmic treatments.
Sources
- Liang L, She K, Ren C, et al. Subretinal Gene Therapy for X-Linked Retinoschisis. New England Journal of Medicine. 2026 Jun 11;394(22):2223-2234. DOI: 10.1056/NEJMoa2515953. PMID: 42269152.
- West China Hospital of Sichuan University. “Top NEJM Publication! West China Hospital’s Research on Gene Therapy for Hereditary Eye Disease.” West China Hospital News. June 11, 2026. https://www.wchscu.cn/public/xwzx.html
- National Center for Biotechnology Information. “Subretinal Gene Therapy for X-Linked Retinoschisis.” PubMed. https://pubmed.ncbi.nlm.nih.gov/42269152/
- Wei X, Li H, Li W, et al. Progression in X-Linked Retinoschisis: A Longitudinal Study Defining Quantitative Biomarkers and Their Implications for Gene Therapy. American Journal of Ophthalmology. 2026 Jun;286:67-80. DOI: 10.1016/j.ajo.2026.02.029.
- Andres-Mateos E, et al. Laterally spreading AAV.SPR enables safe and efficient RS1 delivery to the macula after peripheral subretinal injection. Molecular Therapy. 2026 Mar 11. DOI: 10.1016/j.ymthe.2026.03.014.